Clinical trials - Press Releases

Date	Title	Company
02-Mar-2022	Avance Clinical Announces New Office Opening in Sydney	Avance Clinical
01-Mar-2022	AARDEX Group Joins Innovative IT4Anxiety Project	AARDEX
28-Feb-2022	mdgroup to partner with ERGOMED on new Rare Disease Innovation Center	mdgroup
28-Feb-2022	ERGOMED announces launch of its Rare Disease Innovation Center™	ERGOMED
25-Feb-2022	New preclinical tolebrutinib data demonstrated superior brain penetration and potency	Sanofi
23-Feb-2022	New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA®▼ (guselkumab) at 12 Weeks	Janssen
23-Feb-2022	Results of Novel Clinical Study Show Adults with Moderately to Severely Active Ulcerative Colitis Achieved Higher Rates of Clinical Response, Clinical Remission, and Endoscopic Improvement at 12 Weeks with Guselkumab▼ and Golimumab Combination Therapy Versus Either Monotherapy Alone	Janssen
23-Feb-2022	The Majority of Adults with Moderately to Severely Active Crohn’s Disease in a Phase 2 Study Achieved Clinical Remission and Corticosteroid-Free Remission Through 48 Weeks with TREMFYA®▼ (guselkumab)	Janssen
23-Feb-2022	Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program	Sanofi
23-Feb-2022	Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU	Orion Corporation
22-Feb-2022	Europe’s Only Parallel Trade Conference returns for its 16th Year	SMi Group
22-Feb-2022	NICE Recommends Albireo’s Bylvay®(odevixibat) for All PFIC Types	Albireo Pharma Inc
18-Feb-2022	Darolutamide shows significant increase in overall survival and decrease in disease progression in men with metastatic hormone-sensitive prostate cancer	Bayer
17-Feb-2022	Albireo Announces Publication of the PICTURE Study Highlighting the Caregiver Impact of PFIC, a Rare and Devastating Children’s Liver Disease	Albireo Pharma Inc.
15-Feb-2022	ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10	ProQR Therapeutics N.V.
15-Feb-2022	Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME at the Angiogenesis, Exudation, and Degeneration 2022 Conference	Oxurion NV
15-Feb-2022	mdgroup Appoints Steph Katz as Director of Seacole Health	mdgroup
15-Feb-2022	Velocity Clinical Research makes tech investments to strengthen patient and client engagement in clinical trials	Velocity Clinical Research
15-Feb-2022	Medidata Opens Access to its Patient Insights Program, Enabling Sponsors and CROs to Leverage Proprietary Patient Centricity by Design Process for Clinical Trials	Medidata
15-Feb-2022	Janssen Presents New Data Demonstrating the Combination of Niraparib and Abiraterone Acetate Plus Prednisone Significantly Improved Radiographic Progression-Free Survival as a First-Line Therapy in Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer	The Janssen Pharmaceutical Companies of Johnson & Johnson